TITLE

Health Care Utilization and Cost Burden of Herpes Zoster in a Community Population

AUTHOR(S)
Yawn, Barbara P.; Itzler, Robbin F.; Wollan, Peter C.; Pellissier, James M.; Sy, Lina S.; Saddler, Patricia
PUB. DATE
September 2009
SOURCE
Mayo Clinic Proceedings;Sep2009, Vol. 84 Issue 9, p787
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To conduct a population-based study to assess health care utilization (HCU) and costs associated with herpes zoster (HZ) and Its complications, including postherpetic neuralgia (PHN) and nonpain complications, In adults aged 22 years and older. PATIENTS AND METHODS: Medical record data on HCU were abstracted for all confirmed new cases of HZ from January 1, 1996, through December 31, 2001, among residents of Olmsted County, Minnesota. Herpes zoster-related costs were estimated by applying the Medicare Payment Fee Schedule to health care encounters and mean wholesale prices to medications. All costs were adjusted to 2006 US dollars using the medical care component of the Consumer Price Index. RESULTS: The HCU and cost of the 1669 incident HZ cases varied, depending on the complications Involved. From 3 weeks before to 1 year after Initial diagnosis, there were a mean of 1.8 outpatient visits and 3.1 prescribed medications at a cost of $720 for cases without PHN or nonpain complications compared with 7.5 outpatient visits and 14.7 prescribed medications at a cost of $3998 when complications, PHN, or nonpain complications were present. CONCLUSION: The annual medical care cost of treating Incident HZ cases In the United States, extrapolated from the results of this study In Olmsted County, Is estimated at $1.1 billion. Most of the costs are for the care of Immunocompetent adults with HZ, especially among those 50 years and older.
ACCESSION #
44137670

 

Related Articles

  • Preparation H for shingles. M.O.R. // Cortlandt Forum;9/25/96, Vol. 9 Issue 9, p109 

    Provides information on the treatment for lumbar herpes zoster. Efficacy of topical Preparation H, a hemorrhoid medicine; Antiviral medications for elderly patients.

  • NEW TREATMENT FOR SHINGLES NOW AVAILABLE. Hurley, Mary Lou // RN;Oct94, Vol. 57 Issue 10, p95 

    Reports that Famciclovir (Famvir) has been approved to treat acute herpes zoster or shingles. Dosage; Adverse reactions.

  • Valacyclovir (val-a-CY-clo-veer).  // Drug Topics;9/18/95, Vol. 139 Issue 18, p43 

    Profiles valacyclovir, a drug used in the treatment of shingles or herpes zoster. Medical indications; Valtrex as brand name; How to take and store the medicine; Drugs and foods to avoid; Warnings; Side effects. INSET: When you should not take this medicine..

  • Presentations of herpes. Jordan, Andy // Pulse;8/11/2003, Vol. 63 Issue 32, p37 

    Describes the characteristics of herpes zoster. Details on the unilateral nature of lesions; Diagnosis of herpes zoster affecting the mandibular division of the trigeminal nerve; Efficacy of drugs in treating the disease.

  • In This Issue.  // Clinical Pharmacology & Therapeutics;Dec2010, Vol. 88 Issue 6, p727 

    An introduction to the journal is presented in which the editor discusses articles published within the issue including one by Elizabeth Migoya and colleagues on the use DPP-4 inhibitors and metformin to boast active GLP-1 concentrations, one by Janet Woodcock on the kinds of evidence required...

  • Correction: Changes in Drug Utilization during a Gap in Insurance Coverage: An Examination of the Medicare Part D Coverage Gap.  // PLoS Medicine;Aug2014, Vol. 11 Issue 8, p1 

    A correction to the article "Changes in Drug Utilization during a Gap in Insurance Coverage: An Examination of the Medicare Part D Coverage Gap," in a 2014 issue is presented.

  • Japan bans shingles drug after deaths. Gordon, Hugo // BMJ: British Medical Journal (International Edition);9/10/94, Vol. 309 Issue 6955, p627 

    Reports the shut down of Nippon Shoji, a pharmaceutical company in Japan, due to death of patients from taking drug for shingles. Fatalities due to drug intake; Actions taken by the government in Tokyo; Issues on drug approval system in Japan.

  • Herpes zoster vaccination rates and incidence of shingles.  // OB/GYN Clinical Alert;Mar2011 Pharmacology, p2 

    The article reports on the effectiveness of herpes zoster vaccination in reducing the rate of shingles.

  • Varicella zoster virus vaccine live.  // Reactions Weekly;4/21/2012, Issue 1398, p41 

    The article describes the case of a 6-year-old boy who developed herpes zoster following administration of a single dose of varicella zoster virus vaccine.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics